Search for drugs:
Typing the drug name to query
UMECLIDINIUM
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- QTc interval prolongation was studied in a double-blind, multiple-dose, placebo- and positive-controlled, crossover trial in 86 healthy subjects. Following repeat doses of umeclidinium 500 mcg once daily (8 times the recommended dosage) for 10 days, umeclidinium does not prolong QTc to any clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- R03BB07 - umeclidinium
- R03BB0 -
- R03BB - Anticholinergics
- R03B - "OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS"
- R03 - DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R - RESPIRATORY SYSTEM
- R03AL03 - umeclidinium
- R03AL -
- R03A - "ADRENERGICS, INHALANTS"
- R03 - DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R - RESPIRATORY SYSTEM
- R03AL08 - umeclidinium
- R03AL -
- R03A - "ADRENERGICS, INHALANTS"
- R03 - DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R - RESPIRATORY SYSTEM
Active Ingredient:UMECLIDINIUM BROMIDE
Active Ingredient UNII:7AN603V4JV
Drugbank ID:DB09076
PubChem Compound:11519070
CTD ID:C573971
CAS Number:869185-19-3
Dosage Form(s):aerosol, powder
Route(s) Of Administrator:oral
Daily Dose:
- 0.05 mg/day R03BB07
Chemical Structure: 
SMILE Code:
OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.